Kopran Limited
KOPRAN · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹259.27.
Piotroski F-score 7/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%4.9%
- ✓Low debt (D/E < 0.5)0.29x
- ✓Positive free cash flow
- ✓Revenue growth > 10%36%
- ✓Earnings growing95%
- ✕Net margin ≥ 10%3.8%
- ✓Current ratio > 1.51.51
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✕Altman Z in safe zoneZ 2.27
- ✓Piotroski ≥ 77/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •High Piotroski quality score (7/9).
Weaknesses
- •Low return on equity (4.9%).
Opportunities
- •Earnings growing (95% YoY).
- •Revenue growing (36% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~78% below our estimated fair value.
About Kopran Limited
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hyperten
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.